Pipeline

Now in various stages of development, the products in our pipeline are focused on rare autoinflammatory and autoimmune diseases with unmet needs, and have the potential to address multiple therapeutic areas.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept IL-1α & IL-1β Recurrent pericarditis
(breakthrough therapy designation)
Mid Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab GM-CSFRα Giant cell arteritis Phase 2
Worldwide
KPL-716 OSMRβ Prurigo nodularis Phase 2
Worldwide
Multi-indication pilot study in diseases with a chronic pruritic component End Phase 1
Worldwide
KPL-404 CD40 T-cell dependent, B-cell–mediated indications Phase 1
Worldwide
KPL-045 CD30L T-cell dependent, B-cell–mediated indications Preclin
Worldwide

Every Second Counts!